December 02, 2025

Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium-177–labeled PSMA-I&T (LuPSMA-...

The ASCO Post

December 02, 2025

RNA Testing Uncovers Hidden Gene Fusions in AML

Michigan team finds cryptic leukemia-defining rearrangements missed by standard cytogenetics.

The Pathologist

December 01, 2025

Three Keys to Closing the Communication Gap

New ACOG statement outlines relationship-centered strategies to build trust and improve outcomes, particularly for marginalized patients.

Conexiant

December 01, 2025

Reaching Everyone, Everywhere: Breaking Barriers in Hepatitis C Testing

As global funding declines, decentralized testing, telehealth, and community-based care are helping expand access to HCV diagnosis and treatment

The Pathologist

December 01, 2025

Pushing Boundaries in TMVR

In modern structural heart disease management, the abundance of therapeutic options can be both liberating and paralyzing. When multiple comorbidities converge in a single patient, decisions become exponentially more complex.

Baptist Health South Florida

November 28, 2025

Expanding ERG in Diabetic Eye Care

Why handheld electroretinography fits perfectly within the diabetic retinopathy management workflow

The Ophthalmologist

November 27, 2025

Inside the Race to Detect Neurodegenerative Disease Early

Unlocking a new frontier in diagnosing and understanding complex brain diseases long before symptoms appear

The Pathologist

November 27, 2025

Reviewing the Dry Eye Landscape

Clara C. Chan discusses her team’s recently published DED systematic review

The Ophthalmologist

November 26, 2025

This Week’s Biopharma News: Texas Takes on BMS and Sanofi

This week’s news roundup reports on Texas’s claim against BMS and Sanofi, AstraZeneca’s Maryland investment, Novo Nordisk’s difficult semaglutide admission, and more.

The Medicine Maker